Diabetes medication(s)-Non-insulin injected drugs Posts on Medivizor
Navigation Menu

Diabetes medication(s)-Non-insulin injected drugs Posts on Medivizor

Do glucagon-like peptide-1 receptor agonist drugs reduce heart disease and stroke in patients with diabetes?

Posted by on Nov 11, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study examined if glucagon-like peptide-1 receptor agonist (GLP-1RA) drugs could reduce the rate of heart disease and stroke in patients with Type 2 diabetes (T2D). The authors found that fewer patients who received GLP-1RA drugs developed heart disease or stroke compared to those who received a placebo. Some background...

Read More

Is IDegLira more effective than degludec or liraglutide alone for treating uncontrolled Type 2 diabetes?

Posted by on Sep 16, 2019 in Diabetes mellitus | 0 comments

In a nutshell This study compared IDegLira (Xultophy) to insulin degludec (Tresiba) or liraglutide (Victoza) alone in patients with uncontrolled Type 2 diabetes (T2D). The authors concluded that combined IDegLira was more effective and had fewer side effects than either insulin medication alone. Some background One of the main...

Read More

Does combining insulin glargine with lixisenatide lead to better outcomes?

Posted by on Jul 24, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study compared the effectiveness and safety of a combination of insulin glargine (Lantus) and lixisenatide (Lyxumia), called iGlarLixi, to either drug on its own, in people with type 2 diabetes (T2D). It was determined that iGlarLixi was more effective in reducing HbA1c, and did not increase the risk of side effects. Some background...

Read More

Is IDegLira a suitable treatment for patients with uncontrolled type 2 diabetes?

Posted by on Mar 5, 2018 in Diabetes mellitus | 0 comments

In a nutshell This study investigated the suitability of IDegLira for treating patients with uncontrolled type 2 diabetes. The authors concluded that using IDegLira was safe and effective at reducing blood-sugar levels.  Some background IDegLira is an injectable, fixed-ratio combination of basal insulin (degludec) and a glucagon-like peptide-1...

Read More

Does autoinjected exenatide suspension improve blood glucose control in patients with type 2 diabetes on metformin therapy?

Posted by on Aug 26, 2017 in Diabetes mellitus | 0 comments

In a nutshell This study assessed the safety and effectiveness of a new formulation of exenatide compared to sitaglipitin in patients with sub-optimal blood sugar control taking metformin. This study concluded that exenatide reduced blood sugar levels over 3 months more effectively than sitaglipitin.  Some background There are many blood...

Read More

Insulin and weight gain in type 2 diabetes

Posted by on Sep 12, 2016 in Diabetes mellitus | 0 comments

In a nutshell This study investigated whether type 2 diabetes patients were at increased risk of weight gain when starting insulin treatment. Weight gain differed depending on the patient’s weight when starting insulin treatment. Some background Type 2 diabetes is a progressive disease where the cells in the pancreas that produce insulin,...

Read More

High blood pressure during severe hypoglycemic events can result in reduced kidney function

Posted by on Jun 18, 2016 in Diabetes mellitus | 0 comments

In a nutshell This study investigated whether type 2 diabetes patients were at increased risk of kidney damage if their blood pressure surged during hypoglycemic (dangerously low levels of glucose) events. The study concluded that kidney function did worsen in patients whose blood pressure surged during severe hypoglycemic events.  Some...

Read More